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Abstract
Background: Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible
beneficial impact of statins on MS.
Methodology/Principal Findings: Safety, tolerability and effects on disease activity of atorvastatin given alone or in
combination with interferon-beta (IFN-b) were assessed in a phase II open-label baseline-to-treatment trial in relapsing-
remitting MS (RRMS). Patients with at least one gadolinium-enhancing lesion (CEL) at screening by magnetic resonance
imaging (MRI) were eligible for the study. After a baseline period of 3 monthly MRI scans (months 22 to 0), patients
followed a 9-month treatment period on 80 mg atorvastatin daily. The number of CEL in treatment months 6 to 9 compared
to baseline served as the primary endpoint. Other MRI-based parameters as well as changes in clinical scores and immune
responses served as secondary endpoints. Of 80 RRMS patients screened, 41 were included, among them 16 with IFN-b
comedication. The high dose of 80 mg atorvastatin was well tolerated in the majority of patients, regardless of IFN-b
comedication. Atorvastatin treatment led to a substantial reduction in the number and volume of CEL in two-sided
multivariate analysis (p = 0.003 and p= 0.008). A trend towards a significant decrease in number and volume of CEL was also
detected in patients with IFN-b comedication (p = 0.060 and p= 0.062), in contrast to patients without IFN-b comedication
(p = 0.170 and p= 0.140). Immunological investigations showed no suppression in T cell response but a significant increase
in IL-10 production.
Conclusions/Significance: Our data suggest that high-dose atorvastatin treatment in RRMS is safe and well tolerated.
Moreover, MRI analysis indicates a possible beneficial effect of atorvastatin, alone or in combination with IFN-b, on the
development of new CEL. Thus, our findings provide a rationale for phase II/III trials, including combination of atorvastatin
with already approved immunomodulatory therapy regimens.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating
disease of the central nervous system causing pronounced
neurological disability in younger adults. Although incurable,
several disease-modifying drugs (DMD) such as beta-interferons
(IFN-b), glatiramer acetate, mitoxantrone and recently natalizu-
mab have proven to be effective in reducing the number of
relapses. However, a beneficial influence of DMD on the
progression of disability is far less pronounced and still a matter
of debate. A substantial number of patients do not respond to
current DMD, or refuse long-term adherence to these drugs due to
intolerable side-effects or the inconvenience of parenteral
application. Therefore, the development of oral DMD alternatives
has stimulated scientific research and encouraged clinical trials.
Nevertheless, no orally applicable first line drug has reached
approval for the treatment of relapsing-remitting MS (RRMS) to
date.
Statins are orally administered cholesterol-lowering agents
established in the treatment of cardiovascular diseases [1].
Recently, the presumed immunomodulatory and potential neuro-
protective effects of these 3-hydroxy-3-methylglutaryl (HMG)-CoA
reductase inhibitors have attracted increasing interest [2]. Indeed,
oral statins were effective in preventing and reversing relapsing
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1928
paralysis in experimental autoimmune encephalomyelitis (EAE),
an animal model of MS [3–5]. A previous pilot study with oral
simvastatin given daily over 6 months showed a significant
reduction of contrast-enhancing lesions (CEL) in brain magnetic
resonance imaging (MRI) of 30 RRMS patients compared to a
3 month baseline period [6]. Atorvastatin, which powerfully
suppresses T cell activation and inducible MHC class II expression
on antigen-presenting cells in vitro and in vivo, was not only superior
to other statins in these immunological properties [7], but also
apparently had beneficial effects in a randomized placebo-
controlled treatment trial for rheumatoid arthritis at a daily dose
of 40 mg [8]. These data suggest the potential value of statins in
the treatment of MS. Thus, we investigated the safety, tolerability
and therapeutic potential of high-dose oral atorvastatin (80 mg
daily) given alone or in combination with beta-interferons, and
here report the results of a phase II open-label baseline-to-
treatment trial in a cohort of 41 RRMS patients.
Methods
Study design and participants
A baseline-to-treatment trial was designed to evaluate the safety,
tolerability and efficacy of orally administered atorvastatin in
patients with RRMS. Patients were screened and enrolled in the
outpatient clinic of the Cecilie Vogt Clinic at the Charite´ –
University Medicine Berlin. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1. The protocol was
reviewed and approved by the ethics committee of the Charite´,
and the German Federal Institute for Drugs and Medical Devices
(BfArM) was notified regarding the initiation of the trial. The study
was supervised by an independent data monitoring board. Before
providing informed written consent, all patients were advised of
the approved alternative therapies available to them. Staff
members performing the magnetic resonance imaging (MRI) were
blinded for the clinical course, and physicians assessing the
neurological status of the patients were blinded for the MRI
results.
Sample size calculation was based on an analysis of variance for
repeated measures, and determined with a=5% (two-sided),
power = 80%, a between-level correlation of 0.3, and supposing
2.3161.39 gadolinium (Gd-DTPA)-enhancing lesions (CEL)
before and 1.3060.99 CEL after treatment [6]. Using nQuery
Advisor 5.0 (Statistical Solutions, Cork, Ireland), we calculated a
sample size of n = 34, resulting in a total sample size of n = 41 with
a drop-out rate of 20%. The study population consisted of RRMS
outpatients who fulfilled the panel criteria for clinically definite
MS [9] with an Expanded Disability Status Scale (EDSS) between
0 and 6, age 18–55, and with at least one CEL on a qualifying T1-
weighted brain MRI scan. Clinically active disease at the time of
screening, i.e. symptoms of a relapse, was not a prerequisite for
inclusion. Patients had either not received any DMD for at least
6 months prior to screening (n= 25), or had received a DMD with
either IFN-b-1a 22 mg s.c. 3 times weekly (n = 9) or IFN-b-1b s.c.
every other day (n= 7) for at least 6 months. In the DMD group,
IFN-b treatment was continued throughout the entire study.
Following the qualifying MRI, performed to demonstrate disease
activity (visit 23), the individual study period lasted 12 months,
with a baseline phase of 3 monthly MRI scans and a 9-month
treatment phase. Each patient made 13 regular visits to our
outpatient clinic, with monthly MRI examinations, Multiple
Sclerosis Functional Composite (MSFC) performance, and EDSS
rating conducted every 3 months (at visits 23, 0, 3, 6, 9, 12). After
3 baseline visits, patients received 80 mg atorvastatin (40 mg twice
daily) during the 9-month treatment period. Treatment of relapses
was performed according to current guidelines, with 1 g
methylprednisolone (MP) administered intravenously for 3 to
5 days. Atorvastatin treatment was continued during relapse
treatment. However, in the case of MP administration, subsequent
MRI examination was postponed to ensure an interval of 4 weeks
after the last day of MP application, so as to avoid confounding
effects of corticosteroid treatment on MRI contrast enhancement
[10]. The same interval was adhered to with regards to relapses
requiring MP treatment prior to the screening MRI.
Efficacy endpoints
The primary endpoint was the number of CEL at months 6 to 9
of treatment compared to baseline (months 22 to 0). Secondary
MRI outcome variables included the volume of CEL, number and
volume of hyperintense lesions on T2-weighted scans (‘‘T2-lesion
load’’), volume of T1-hypointense lesions (‘‘black hole’’ = BH),
whole brain magnetization transfer ratio (MTR), and apparent
diffusion coefficient (ADC) of the normal appearing white matter
(NAWM) at months 6 to 9 compared to baseline. Further
secondary endpoints were changes in EDSS and MSFC scores.
Other planned targets were changes in various peripheral immune
cell parameters from the baseline period to the treatment phase
(months 6 and 9).
Safety and tolerability
Safety and tolerability of the study drug were assessed by
monthly MRI scans, physical and neurological examination,
relapse assessment, electrocardiogram and vital signs (blood
pressure, pulse). Laboratory examinations (performed at visits
23, 0, 1, 3, 6 and 9) recorded red and white blood counts, liver
enzymes (ALT, AST, c-GT), electrolytes (sodium, potassium,
chloride), creatinine and creatine kinase (CK). At months 0 and 9,
total cholesterol, HDL and LDL cholesterol, and triglycerides
were investigated.
Procedures
Magnetic resonance imaging. MRI measurements were
performed on a scanner operating at 1.5 T (Siemens Sonata,
Siemens Medical Systems, Erlangen, Germany). A triple echo
spin-echo sequence (TR 5,780 ms, TE1 13 ms, TE2 81 ms, TE3
121 ms, 3 mm slice thickness and 44 contiguous axial slices) was
used to obtain proton density and T2-weighted images.
Additionally, we applied a fluid-attenuated inversion recovery
sequence (TIRM, TR 10,000 ms, TE 108 ms, TI 2,500 ms, 3 mm
slice thickness and 44 contiguous axial slices) and a high resolution
3-dimensional T1-weighted sequence (MPRAGE, TR 2,110 ms,
TE 4.38 ms, TI 1,100 ms, flip angle 15u, resolution 1 mm3).
Conventional spin-echo T1-weighted (TR 1,060 ms, TE 14 ms,
3 mm slice thickness and 44 contiguous axial slices) and
magnetization-prepared images (MTI, TR 1,290 ms, TE 14 ms,
3 mm slice thickness and 44 contiguous axial slices) were obtained
before and 5 minutes after injection of 0.1 mmol/kg Gd-DTPA
(Magnevist, Bayer-Schering, Berlin, Germany). An epi-planar
(EPI) diffusion-weighted sequence (DWI, TR 9,400 ms, TE
118 ms, 3 mm slice thickness, matrix 1286128, b values 1 and
1,000 s/mm2) was acquired in 3 directions for the calculation of
the ADC. A series of axial, coronal and sagittal images was
obtained to create a reference scan for subsequent accurate
repositioning of patients at follow-up. The axial slices were
positioned to run parallel to a line that joined the most inferior-
anterior and inferior-posterior parts of the corpus callosum. Image
quality was reviewed according to pre-determined criteria.
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Raw data were transferred to a Linux workstation and
processed following a semi-automated procedure described
previously [11], including an image coregistration (FMRIB’s
Linear Image Registration Tool, FMRIB Analysis Group,
University of Oxford, Oxford, UK) and inhomogeneity correction
routine embedded into the MedX v.3.4.3 software package
(Sensor Systems Inc., Sterling, VA, USA). Bulk white matter
lesion load and lesion count of T2-weighted scans, as well as
number and volume of CEL and hypointense lesions on T1-
weighted scans, were routinely measured using the MedX v.3.4.3
software package. MTR was calculated in MIPAV (Medical Image
Processing, Analysis, and Visualization, CIT-NIH, Bethesda, MD,
USA) as previously described [12]. MRI analyses were conducted
in an anonymized way, applying a semi-automated procedure.
Experienced raters ( JW, HW and MH) were blinded to clinical
data and time of investigation.
Immunological examinations. In light of the reported anti-
proliferative and anti-inflammatory properties of statins and IFN-b
[13], we performed in vitro assays to test the synergy of these agents.
T cell proliferation and gene expression of the tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL) were
chosen as a response marker for IFN-b treatment [14]. The
proliferation of myelin basic protein (MBP)-specific T cell lines
towards anti-CD3/anti-CD28 was measured in the presence of
increasing doses of atorvastatin (1 nM–50 mM) and IFN-b-1a
(0.0001–100,000 IU/ml) by a standard 3H thymidine incor-
poration assay. TRAIL expression was measured in peripheral
blood mononuclear cells (PBMC) treated with atorvastatin
(100 nM–1 mM) and IFN- b-1a (1–10,000 IU/ml) for 4 h using
real-time quantitative reverse-transcriptase PCR (rtPCR), and
is reported as relative gene expression normalized to the
housekeeping gene GAPDH, as previously described [14]. Drug
interactions were investigated using isobolographic analyses as
previously described [15].
In patients, we concentrated on proliferative responses and
expression of key cytokines. All immunological measurements
were performed by independent investigators who were unaware
of the clinical and MRI data. For the analysis of proliferative
responses, PBMC were isolated from patients’ whole blood using
standardized protocols, and plated on freshly thawed 96-well
culture plates containing increasing doses of a recall antigen
cocktail consisting of the following: CMV viral lysate diluted at
1:1,000 (ABI, Columbia, MA, USA); C. albicans (Candidin,
Allergopharma, Reinbek, Germany) at a final concentration of
10 ml/ml; purified tuberculin (PPD, Chiron Behring, Liederbach,
Germany) at a final dilution of 1:250; tetanus toxoid (Tetasorbat
SSW, SmithKline Beecham Pharma, Munich, Germany) at
1:1,000; and influenza antigen vaccine 2002 (Aventis Pasteur,
Lyon, France) at 1:1,000. ConA (Sigma, Munich, Germany) was
used as an antigen-independent activator. Proliferation was
measured in counts per minute (cpm) by a standard 3H thymidine
incorporation assay, and maximum proliferative response was
calculated on an index between the unstimulated control and the
maximum proliferation counts. Soluble interleukin (IL)-4, IL-10,
TNF-a and IFN-c were measured after 24 h ConA stimulation by
cytometric multiplexing with the BDTM Cytometric Bead Array
(CBA), following the manufacturer’s instructions (Becton Dick-
inson Biosciences, Heidelberg, Germany). TRAIL expression was
measured by rtPCR from whole blood collected in PAXgeneTM
Blood RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland).
Blood was processed using the PAXgeneTM Blood RNA Kit,
following the manufacturer’s instructions. Reverse transcription,
amplification and design of TaqMan primer and probes were
performed as previously described [14].
Statistical analysis. As required by the inclusion criteria,
brain MRI at enrolment showed disease activity with respect to the
occurrence of CEL. However, to achieve a stable baseline as a
prerequisite for adequate statistical testing, and thus to avoid any
possible statistical bias, we excluded data from this first MRI from
further statistical analysis and defined months 22 to 0 as the
baseline period. Baseline was compared to the treatment period
months 6 to 9, following the hypothesis that presumed effects of
atorvastatin on inflammatory disease activity would be detectable
after at least 6 months of treatment [6,8]. Therefore, statistical
analyses were carried out only in patients who had completed at
least 6 months of atorvastatin treatment. For the analyses, we used
nonparametric multivariate analysis of variance (MANOVA) for
repeated measurements, which allowed all 4 treatment time points
and all 3 baseline measurements to be analyzed simultaneously
with respect to time course [16]. For exploratory comparison of
the two subgroups of patients with or without IFN-b comedication,
this analysis was also carried out in a two-factorial design. The
Wilcoxon signed ranks test was used to examine changes in routine
laboratory parameters between the baseline and treatment periods
and the annualized relapse rate before and during atorvastatin
treatment. Significance was assessed at the p,0.05 level.
Regarding the primary endpoint of CEL number, this p-level is
to be understood in a confirmatory sense. P-values of secondary
endpoints and in subgroup analyses are, however, to be
understood in an exploratory sense and adjustments for multiple
comparisons were therefore not carried out. All numerical
calculations were performed using SPSS 13 (SPSS Inc., Chicago,
IL, USA) and SAS 9.1 (SAS Inc., Cary, NC, USA).
Results
Primary and secondary endpoints
Of the 80 patients screened, 41 were subsequently enrolled in
the trial (Figure 1). The clinical features of these patients are
summarized in Table 1. Thirty-nine patients were excluded
because they did not show a CEL on the qualifying MRI scan.
Five patients discontinued the study before completion of at least
6 months of atorvastatin treatment. Thus, data from 36 patients
were available for the final analysis of the primary endpoint.
Treatment with high-dose atorvastatin resulted in a significant
reduction of CEL number compared to baseline in the
multivariate analysis (p = 0.003, Table 2). Concerning the two
subgroups, we found a trend towards a significant CEL number
reduction over time in patients with IFN-b comedication
(p = 0.060), but not in patients without IFN-b comedication
(p = 0.170, Table 2). Direct exploratory comparison of these two
groups using a two-factorial MANOVA design showed no
differences (p = 0.274).
Concerning the CEL volume as a secondary endpoint, we found
a similar pattern: multivariate analysis revealed a significant
reduction in CEL volume compared to baseline in the analyzable
population as a whole (p = 0.008). In the subgroup with IFN-b
comedication, there was a trend towards a significant reduction of
CEL volume (p= 0.062) which was not the case in the group
without IFN-b comedication (p = 0.140, Table 2). Again, no
differences between groups with and without IFN-b were observed
in the direct two-factorial MANOVA comparison (p = 0.315).
Number and volume of T2 lesions increased in both the entire
study population and the two subgroups over time without
relevant inter-group differences. Whole brain MTR increased
significantly during our study only in the IFN-b comedication
group, but not in patients without IFN-b comedication (Table 2).
Black hole evolution and NAWM ADC did not change over time
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either in the entire study population or in the subgroups (Table 2).
EDSS scores remained unchanged over the entire study period
(p = 0.665, Table 2). Better MSFC scores (Table 2) resulted from
improvements in the PASAT (Paced Auditorial Serial Addition
Test) and the 9-HPT (9-Hole Peg Test) subtests, while the TWT
(Timed Walk Test) remained unchanged (data not shown). In the
study population as a whole, the mean annualized relapse rate 6
standard deviation (SD) was 1.4661.1 in the year prior to
atorvastatin treatment and 0.6860.99 during atorvastatin treat-
ment (p,0.001). In the subgroup of patients without IFN-b
comedication the relapse rate was 1.461.0 in the year before
treatment and 0.6461.0 during treatment (p = 0.002). In the IFN-
b comedication group the relapse rate was 1.6361.26 before
treatment and 0.7560.97 during treatment (p = 0.049).
Figure 1. Flow chart of study patients.
doi:10.1371/journal.pone.0001928.g001
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Concerning immunological effects, our in vitro studies indicated
synergistic activity of atorvastatin and IFN-b, which was the basis
for introducing the combination therapy arm in the clinical trial.
Using MBP-specific T cell lines we performed proliferation assays
to measure inhibition in T cell response following increasing doses
of both drugs. The EC50 (concentration producing 50% of
maximum proliferation inhibition) for atorvastatin was 3.2 mM
and for IFN-b 270 IU/ml. From these two EC50 values we were
able to construct an isobologram and theoretically determine
combinations of low concentrations of both drugs that would
potentially have a supra-additive effect (synergism) (see Methods).
The lowest concentration combination tested, which in fact
revealed EC50 in culture and fell within the synergy zone of the
isobologram, was IFN-b, atorvastatin: 100 IU/ml, 0.1 mM. For
the expression of TRAIL, which our previous work had suggested
to be a response marker for IFN-b therapy in MS [14], the EC50 of
atorvastatin was 0.6 mM, and for IFN-b 900 IU/ml. The lowest
concentrations exhibiting synergy were IFN-b, atorvastatin:
100 IU/ml, 0.1 mM.
Applying 80 mg atorvastatin daily in vivo, however, revealed
neither an overall antiproliferative effect on peripheral T cells
(mean stimulation index 6 SD upon recall antigen challenge at
baseline: 112.76124.6, on treatment: 92.7698.7, p = 0.26; mean
stimulation index 6 SD upon ConA challenge at baseline:
83.1682.8, on treatment: 85.4679.8, p = 0.66) nor an effect on
basal TRAIL levels (mean relative gene expression 6 SD at
baseline: 15.5612.3, on treatment: 20.9620.8, p= 0.23). Further-
more, while IL-4 levels did not change over time (mean IL-4 level
6 SD at baseline: 86.4 pg/ml648.1, on treatment: 92.4 pg/
ml653.5, p = 0.47), we observed a significant increase in the
regulatory cytokine IL-10 (mean IL-10 level 6 SD at baseline:
202.3 pg/ml699.0, on treatment: 256.4 pg/ml6140.1, p = 0.02).
We observed a borderline increase for TNF-a levels (mean level 6
SD at baseline: 1,661.3 pg/ml6807.0, on treatment: 1,914.3 pg/
ml61,132.8, p = 0.05), while IFN-c levels remained unchanged
(mean level 6 SD at baseline: 9,148.1 pg/ml66,598.0, on
treatment: 10,899.4 pg/ml611,208.1, p = 0.42).
Treatment adherence and tolerability
Serum levels of total cholesterol, LDL cholesterol and
triglycerides significantly decreased from baseline until the end
of the study, while HDL cholesterol remained unchanged,
indicating patient compliance and pharmacological effects of
atorvastatin in our cohort (Table 3). Of the 41 patients enrolled in
this study, 5 patients discontinued before completion of 6 months
of atorvastatin treatment (Table 4), 3 of them due to a severe
relapse (pat. #1 and pat. #3 with brainstem symptoms; pat. #2
with gait disturbance). In the remaining evaluable study
population (n= 36), 15 participants (13 without IFN-b comedica-
tion, 2 with IFN-b comedication) were treated per protocol, i.e.
these patients received 80 mg atorvastatin daily throughout the
entire study (PP group); in 14 patients (6 without IFN-b comedica-
tion, 8 with IFN-b comedication) minor protocol violations (MPV)
occurred, e.g. these patients received a mean daily dose (MDD) of at
least 70 mg atorvastatin throughout the study (MDD 76.2 mg, MPV
group); 7 patients (5 without IFN-b comedication, 2 with IFN-b
comedication) caused major protocol violations (MAJ) by incorpo-
rating a mean daily dose of less than 70 mg atorvastatin (MDD
48.4 mg, MAJ group) (Table 5). The high dose of 80 mg atorvastatin
was well tolerated in the majority of patients, regardless of IFN-b
comedication. 16 patients experienced a temporary mild (less than
1.5-fold the upper limit) elevation of liver enzymes with no consistent
timeframe of occurrence after the initiation of atorvastatin treatment.
In 5 subjects a clinically relevant elevation of transaminases was
detected (up to 4-fold the upper limit), though after temporary
discontinuation of the study drug or dose reduction these parameters
returned to normal. In 10 patients (24.4%), an elevation of serum
CK was observed of less than 1.5-fold the upper limit in 6 cases and
more than 1.5-fold in 4 patients, resulting in a dose reduction or
withdrawal from the study (see details below on protocol violations,
and Tables 4 and 6). However, no cases of myoglobinuria and/or
rhabdomyolysis occurred. Further side effects are listed in Table 6.
Reasons for protocol violations were as follows: 11 patients from the
MPV group had a short run-in phase of 1 or 2 weeks to improve
tolerability of atorvastatin (start with 20 mg twice daily). This minor
protocol violation was initiated during the course of the study,
following up several patients who experienced reduced tolerability
and side effects (nausea, diarrhoea) when immediately starting on
80 mg daily. One patient had a temporary dose reduction to 40 mg
daily owing to increase of AST more than 2-fold the upper limit. A
second patient had a temporary dose reduction to 40 mg due to an
elevation of CK 1.5-fold the upper limit, and a third patient
temporarily reduced the dose because of nausea and dizziness under
the original dosage. Reasons for substantial dose reduction in the
MAJ group were as follows: 4 patients temporarily discontinued or
reduced the daily atorvastatin dose to 20 mg or 40 mg because of an
elevation of liver enzymes up to 4-fold the upper limit, though
without clinical signs of hepatic dysfunction; one patient experienced
an elevation of CK 2.5-fold the upper limit, complaining of diffuse
muscle pain; another patient experienced recurrent diarrhoea and
later developed a lumbar herpes zoster on 80 mg atorvastatin; a
further patient withdrew after 7 months of treatment owing to a 5-
fold increase in CK and intolerable myalgias. One additional patient
withdrew prematurely owing to a 10-fold increase in CK (pat. #4,
Table 4).
Discussion
Our study – the longest statin treatment in MS patients reported
thus far, and the first clinical trial examining a combination
treatment of atorvastatin with IFN-b – suggests that treatment
with high-dose atorvastatin over a period of 9 months is safe and
Table 1. Clinical and demographic baseline data of patients.
Sex (m, f) Age (yrs)
Duration of
disease in
months
Duration of IFN-b
pre-treatment in
months
EDSS at
inclusion
Total no. of
relapses since
disease onset
No. of relapses
12 months prior to
treatment
Total cohort (n = 41) 20/21 35.4 (19–51) 84 (2–317) n.a. 1.67 (1.4, 0–6) 4.07 (2.6, 1–12) 1.46 (1.1, 0–4)
w/IFN-b (n = 16) 9/7 37.9 (24–48) 116.3 (26–317) 48 (7–115) 2.50 (1.5, 0–6) 5.75 (2.6, 3–12) 1.63 (1.3, 0–4)
w/o IFN-b (n = 25) 11/14 33.9 (19–51) 63.4 (2–229) n.a. 1.14 (1.1, 0–4) 3 (2.1, 1–10) 1.4 (1.0, 0–4)
Values are mean (standard deviation, range). Abbreviations: w, w/o IFN-b: with/without interferon-beta pre-treatment/comedication.
doi:10.1371/journal.pone.0001928.t001
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well tolerated in the majority of patients. Moreover, we observed a
pronounced reduction in number and volume of CEL under
treatment when compared to baseline. These results are consistent
with, and go beyond, those of a recent report describing the effects
of 80 mg simvastatin given to 30 patients with RRMS over a
period of 6 months [6]. Regarding primary endpoints, our data
are comparable to this study as we observed (i) a decrease in mean
CEL number from 2 to 1.52 (as compared to a decrease from 2.31
to 1.30 reported by Vollmer et al. [6]), and (ii) a reduction of CEL
volume from 120 mm3 to 106 mm3 (as compared to a decrease
from 234 mm3 to 139 mm3 reported by Vollmer et al.). However,
in the latter study, mean T2 lesion volume at baseline was
considerably higher than in our cohort (27019 mm3 vs.
5142 mm3) and, in contrast to our results, did not increase
further. This may reflect the difference in clinical baseline
parameters between the two study populations occurring as a
result of lower mean age (35 vs. 44 yrs) and a lower EDSS at study
entry (1.7 vs. 2.8) in our patient group.
The baseline-to-treatment study design used here may be
subject to certain probabilistic phenomena such as regression to
the mean, i.e. an expected decrease of disease activity in a given
patient population with high disease activity at study onset.
However, by applying 3 monthly MRI scans prior to treatment
initiation, thus resulting in a stable baseline as a prerequisite for
adequate statistical testing, and by performing a nonparametric
MANOVA, we used all means possible to avoid statistical bias.
These evaluation methods also clearly distinguish our study from
the previous study on simvastatin in MS [6], with its univariate
analysis of mean values, although both use the same study
design. In fact, this baseline-to-treatment trial design has been
successfully used several times in the recent past to prove
principles of treatment strategies in MS without the necessity for
a long placebo period, the latter raising serious ethical concerns
[17–19].
A further novelty in our study, besides the use of atorvastatin in
MS, is the inclusion of patients with MRI activity despite IFN-b
pre-treatment, who then received add-on medication. The
scientific rationale for applying this combination therapy in this
clinical trial originated from our observations of a clear
immunomodulatory synergy of both drugs in culture assays.
Indeed, applying multivariate analysis we observed a trend
towards a significant reduction in CEL number and volume over
time in the group with IFN-b comedication, but not in those
patients undergoing atorvastatin monotherapy. However, sample
sizes in both subgroups were too small and the differences in the
statistical tests too minor to support the conclusion that
combination therapy may be more efficacious than atorvastatin
monotherapy. In addition, direct exploratory between-group
comparisons (using two-factorial MANOVA) were unable to
detect a more pronounced effect of the combination therapy on
CEL number and volume. This discrepancy may be due to small
and unequal sample size numbers in the two subgroups (24 vs. 12
patients), or to differences between the groups already at baseline,
or may indeed reflect a non-superiority of the combination
therapy. As our study was designed to assess longitudinal effects
of atorvastatin, and not to compare groups of patients with and
without IFN-b comedication, our data are not intended to draw a
firm conclusion regarding treatment efficacy of a combination of
atorvastatin with IFN-b. This conclusion is also undermined by
other MRI parameters such as MTR and ADC, which only
partially dichotomized the 2 subgroups in favour of the
comedication group. On the other hand, the results of our
MRI analyses argue against a possible detrimental effect of an
atorvastatin/IFN-b combination therapy on disease course, as
T
a
b
le
2
.
P
ri
m
ar
y
an
d
se
co
n
d
ar
y
M
R
I
an
d
cl
in
ic
al
e
n
d
p
o
in
ts
in
th
e
b
as
e
lin
e
an
d
tr
e
at
m
e
n
t
p
e
ri
o
d
s
(m
e
an
,
st
an
d
ar
d
d
e
vi
at
io
n
,
ra
n
g
e
).
B
a
se
li
n
e
(m
o
2
2
/0
),
m
e
a
n
,
S
D
,
ra
n
g
e
T
re
a
tm
e
n
t
(m
o
+6
/+
9
),
m
e
a
n
,
S
D
,
ra
n
g
e
P
(M
A
N
O
V
A
)
A
ll
a
n
a
ly
z
e
d
(3
6
)
w
/o
IF
N
-b
(2
4
)
w
/I
F
N
-b
(1
2
)
A
ll
a
n
a
ly
z
e
d
(3
6
)
w
/o
IF
N
-b
(2
4
)
w
/I
F
N
-b
(1
2
)
A
ll
w
/o
IF
N
-b
w
/I
F
N
-b
C
EL
(n
o
)
2
(2
.6
)
(0
–
1
3
.3
)
2
.2
6
(3
.0
)
(0
–
1
3
.3
)
1
.4
7
(1
.4
1
)
(0
.3
–
4
.7
)
1
.5
2
(2
.1
8
)
(0
–
8
.7
5
)
1
.8
8
(2
.5
8
)
(0
–
8
.7
5
)
0
.8
1
(0
.6
2
)
(0
–
1
.7
5
)
0
.0
0
3
0
.1
7
0
0
.0
6
0
C
EL
vo
l
(m
m
3
)
1
2
0
(1
7
0
)
(0
–
6
7
2
)
1
4
1
(1
9
7
)
(0
–
6
7
2
)
7
9
(9
4
)
(4
–
3
3
6
)
1
0
6
(1
7
7
)
(0
–
8
0
6
)
1
3
3
(2
0
9
)
(0
–
8
0
6
)
5
0
(5
5
)
(0
–
1
4
8
)
0
.0
0
8
0
.1
4
0
0
.0
6
2
T
2
le
si
o
n
co
u
n
t
(n
o
)
4
5
.6
(2
8
.9
)
(2
–
1
3
6
)
4
1
.6
(2
6
.5
)
(2
–
1
1
1
)
5
3
.6
(3
3
)
(2
2
–
1
3
6
)
4
9
.4
(2
9
.5
)
(2
–
1
3
9
)
4
5
(2
7
.4
)
(2
–
1
2
0
)
5
8
(3
2
.8
)
(2
4
–
1
3
9
)
,
0
.0
0
1
0
.0
0
2
0
.0
0
8
T
2
le
si
o
n
vo
l
(m
m
3
)
5
1
4
2
(4
0
6
5
)
(2
1
7
–
2
0
7
6
6
)
4
1
5
5
(2
8
8
1
)
(2
1
7
–
1
1
2
6
8
)
7
1
1
6
(5
3
7
0
)
(2
0
7
7
–
2
0
7
6
6
)
5
7
9
7
(4
5
6
6
)
(7
9
–
2
4
0
9
7
)
4
7
5
7
(3
2
5
1
)
(7
9
–
1
2
2
5
5
)
7
8
7
9
(6
0
9
6
)
(2
3
3
6
–
2
4
0
9
7
)
0
.0
0
8
0
.0
5
3
0
.0
0
3
B
H
vo
l
(m
m
3
)
3
3
1
(5
4
4
)
(0
–
2
2
8
6
)
2
1
1
(3
8
9
)
(0
–
1
3
5
6
)
5
6
9
(7
3
1
)
(0
–
2
2
8
6
)
3
3
8
(5
7
1
)
(0
–
2
4
7
6
)
2
1
1
(3
7
7
)
(0
–
1
3
7
8
)
5
9
6
(7
9
6
)
(0
–
2
4
7
6
)
0
.5
6
0
0
.3
2
1
0
.6
8
8
M
T
R
W
h
o
le
b
ra
in
0
.1
9
7
(0
.0
1
1
)
(0
.1
7
0
–
0
.2
2
5
)
0
.1
9
9
(0
.0
1
1
)
(0
.1
7
9
–
0
.2
2
5
)
0
.1
9
1
(0
.0
1
)
(0
.1
7
0
–
0
.2
0
6
)
0
.1
9
7
(0
.0
1
1
)
(0
.1
7
1
–
0
.2
1
4
)
0
.1
9
8
(0
.0
1
)
(0
.1
7
3
–
0
.2
1
2
)
0
.1
9
6
(0
.0
1
3
)
(0
.1
7
1
–
0
.2
1
4
)
0
.3
5
0
0
.3
3
1
0
.0
2
3
A
D
C
N
A
W
M
7
3
.7
(5
)
(6
8
.3
–
8
9
.9
)
7
3
.4
(5
.3
)
(6
8
.3
–
8
9
.9
)
7
4
.3
(4
.6
)
(6
9
.3
–
8
4
.8
)
7
3
.3
(4
.8
)
(6
7
.4
–
8
8
)
7
3
.1
(4
.8
)
(6
7
.5
–
8
8
)
7
3
.8
(5
.1
)
(6
7
.4
–
8
5
.8
)
0
.1
0
8
0
.0
6
6
0
.6
5
6
ED
SS
1
.5
8
(1
.3
5
)1
(0
–
6
)
1
.1
9
(1
)1
(0
–
4
)
2
.3
8
(1
.6
3
)1
(0
–
6
)
1
.5
7
(1
.3
2
)
(0
–
6
)
1
.1
6
(0
.9
3
)
(0
–
4
)
2
.4
(1
.6
2
)
(0
–
6
)
0
.6
6
5
0
.5
0
2
0
.7
1
2
M
SF
C
0
.2
(0
.6
9
)
(2
2
.3
5
–
1
.0
7
)
0
.4
2
(0
.4
7
)
(2
0
.5
3
–
1
.0
7
)
2
0
.2
3
(0
.8
6
)
(2
2
.3
5
–
0
.5
2
)
0
.4
6
(0
.6
3
)
(2
2
.1
4
–
1
.1
9
)
0
.6
5
(0
.4
2
)
(2
0
.1
5
–
1
.1
9
)
0
.0
7
1
(0
.8
1
)
(2
2
.1
4
–
1
.0
4
)
,
0
.0
0
1
,
0
.0
0
1
0
.0
3
5
P
-v
al
u
e
s
ar
e
ca
lc
u
la
te
d
b
y
m
e
an
s
o
f
m
u
lt
iv
ar
ia
te
an
al
ys
is
(M
A
N
O
V
A
).
1
m
o
n
th
0
.A
b
b
re
vi
at
io
n
s:
SD
:s
ta
n
d
ar
d
d
e
vi
at
io
n
;w
,w
/o
IF
N
-b
:w
it
h
/w
it
h
o
u
t
in
te
rf
e
ro
n
-b
e
ta
p
re
-t
re
at
m
e
n
t/
co
m
e
d
ic
at
io
n
;C
EL
:c
o
n
tr
as
t
e
n
h
an
ci
n
g
le
si
o
n
s;
B
H
:b
la
ck
h
o
le
;M
T
R
:m
ag
n
e
ti
za
ti
o
n
tr
an
sf
e
r
ra
ti
o
;A
D
C
:a
p
p
ar
e
n
t
d
if
fu
si
o
n
co
e
ff
ic
ie
n
t;
N
A
W
M
:
n
o
rm
al
ap
p
e
ar
in
g
w
h
it
e
m
at
te
r;
ED
SS
:
Ex
p
an
d
e
d
D
is
ab
ili
ty
St
at
u
s
Sc
al
e
;
M
SF
C
:
M
u
lt
ip
le
Sc
le
ro
si
s
Fu
n
ct
io
n
al
C
o
m
p
o
si
te
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
0
1
9
2
8
.t
0
0
2
Atorvastatin in RRMS
PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e1928
recently suggested [20]. This is supported by our clinical data: the
decrease of the annualized relapse rate from the pre-treatment to
the treatment period was comparable in both subgroups, and the
number of relapses and proportion of patients suffering relapses
while on atorvastatin treatment did not significantly differ
between patients with and without IFN-b comedication. The
same was also true of the change in EDSS and MSFC. Five
patients dropped out of the study before completion of 6 months
of atorvastatin treatment; two of them underwent combination
therapy with IFN-b and experienced a relapse. It does not seem
reasonable to hold the short-lasting combination treatment
period responsible for disease exacerbation, all the more so as
these patients also exhibited an active disease course prior to
introduction of atorvastatin. Two further patients with IFN-b
pre-treatment, who discontinued the study for reasons other than
exacerbation after 5 months of atorvastatin treatment, did not
experience relapses and displayed constant or even decreased
CEL numbers/volume and T2 lesion load.
Moreover, according to our data, neither safety consider-
ations nor side effects argue against a monotherapy with
atorvastatin or a combination with IFN-b. Although certain
adverse events, such as elevated CK, occurred more frequently
in the IFN-b comedication group, only one patient from this
group had to be withdrawn from the study due to sustained CK
elevation; the second patient discontinuing atorvastatin for this
same reason was in the atorvastatin monotherapy group. The
proportion of patients experiencing an elevation of liver
enzymes was comparable between both groups, arguing against
any additional hepatotoxicity from combination therapy.
Moreover, we noticed a reduced general tolerability, mostly
evident in nausea and gastrointestinal side effects, irrespective of
IFN-b pre-treatment, when immediately starting with 80 mg
atorvastatin. These side effects required a temporary dose
reduction and were therefore the principle reason for minor
protocol violations. We therefore introduced a short run-in
phase of 2 to 4 weeks, which should also be considered for
further clinical trials with atorvastatin.
The underlying mechanisms through which statins may exert
their beneficial influence on inflammatory activity in MS patients
have not yet been fully elucidated. Previous data suggested a
pronounced regulation of T lymphocytes, including a shift from T
helper 1 to T helper 2 cells and direct interference in HMG-CoA-
reductase-dependent T cell signalling pathways [4,5,21,22]. Since
we found neither a disturbed proliferative response nor an
inhibition of pro-inflammatory cytokines in our patients, high-
dose atorvastatin apparently does not exhibit overall peripheral
immunosuppressive effects. An upregulation of IL-10, however,
indicates an atorvastatin-mediated involvement of regulatory
mechanisms in vivo.
In summary, we report that treatment with high-dose
atorvastatin over 9 months was safe and well tolerated in the
majority of our patients, regardless of IFN-b co-medication.
Moreover, our data based on MRI surrogate measures for disease
activity suggest possible beneficial effects of atorvastatin on lesion
formation in patients with active disease. However, it remains to
be investigated in future clinical trials whether the immunomod-
ulatory effects observed here may indeed have an impact on the
clinical disease course in RRMS. Thus, randomized, controlled
trials with atorvastatin versus placebo given as an add-on to
approved immunomodulators are warranted. Such a study design
would meet both ethical concerns as well as scientific and
methodological demands.
Table 3. Change of cholesterol and triglyceride serum levels under treatment with atorvastatin in the evaluable study population
(n = 36). SD: standard deviation.
Before treatment (mo 0)
(mean in mg/dl, SD, range)
End of treatment (mo +9)
(mean in mg/dl, SD, range)
P (Wilcoxon Signed
Ranks Test)
Cholesterol
- Total 180.1 (33.3, 109–292) 123.5 (23.6, 75–200) ,0.001
- LDL 104.9 (29.6, 36–191) 51.2 (17.3, 13–106) ,0.001
- HDL 58.6 (14.1, 29–87) 60.9 (14.1, 26–94) 0.231
Triglycerides 113.1 (56, 42–249) 92.7 (53.2, 28–264) 0.002
doi:10.1371/journal.pone.0001928.t003
Table 4. Clinical characteristics and MRI data of patients with premature study withdrawal.
Pat. Sex, age IFN-b treatment WD mo. CEL (no) BL CEL (no) Tx CEL (vol) BL CEL (vol) Tx Reason for WD, comments
#1 M, 39 IFN-b-1a 22 mg +4 0.66 2.5 98.25 193.8 Relapse, active disease: 2 relapses in 12 mo prior to
inclusion, dose augmentation to IFN-b-1a 44 mg
#2 M, 44 IFN-b-1a 22 mg +1 0 0 0 0 Relapse, preceding relapse during BL, switch to IFN-b-
1a 44 mg and shortly thereafter mitoxantrone
#3 M, 27 None +4 6 3.5 423.5 171.7 Relapse, active disease: 2 relapses in 12 mo prior to
inclusion, 2 relapses in BL, started IFN-b-1a 44 mg
#4 M, 33 IFN-b-1b +5 0.33 0 21.5 0 10-fold increase in creatine kinase, no relapse or
progression of disability during treatment period
#5 M, 24 IFN-b-1b +5 0 0 0 0 Change of residence, no relapse or progression of
disability during treatment period
For CEL, mean values of BL (baseline) and treatment period (Tx) until discontinuation are given. Abbreviations: WD: withdrawal; CEL: contrast enhancing lesions.
doi:10.1371/journal.pone.0001928.t004
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